Search
for

    Learn

    5 / 801 results

    Research

    5 / 38 results

    Community Join

    5 / 1000+ results

      community GT20029. Kintor Pharma’s Product

      in Research/Science  12 upvotes 3 years ago
      The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

      community Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World’s First Topical Use PROTAC Compound

      in Research/Science  128 upvotes 3 years ago
      The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

      community Whats the deal with TDM-105795?

      in Research/Science  4 upvotes 2 months ago
      TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

      community Kintor’s GT20029 Phase 1 success

      in Update  74 upvotes 3 years ago
      Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.